HomeCompareADAP vs GIS

ADAP vs GIS: Dividend Comparison 2026

ADAP yields 4123.71% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADAP wins by $9626865092698.91M in total portfolio value
10 years
ADAP
ADAP
● Live price
4123.71%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9626865092698.99M
Annual income
$9,188,540,292,149,123,000.00
Full ADAP calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — ADAP vs GIS

📍 ADAP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADAPGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADAP + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADAP pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADAP
Annual income on $10K today (after 15% tax)
$350,515.46/yr
After 10yr DRIP, annual income (after tax)
$7,810,259,248,326,754,000.00/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, ADAP beats the other by $7,810,259,248,326,740,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADAP + GIS for your $10,000?

ADAP: 50%GIS: 50%
100% GIS50/50100% ADAP
Portfolio after 10yr
$4813432546349.54M
Annual income
$4,594,270,146,074,569,700.00/yr
Blended yield
95.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADAP right now

ADAP
Analyst Ratings
9
Buy
4
Hold
3
Sell
Consensus: Buy
Price Target
$2.83
+5735.1% upside vs current
Range: $1.00 — $4.00
Altman Z
-15.6
Piotroski
0/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADAP buys
0
GIS buys
12
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-09-29
Dan Newhouse🏢 House$GIS▲ Buy$1,001 - $15,0002025-08-18
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$GIS▲ Buy$1,000 - $15,0002025-08-04
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-24
Lisa McClain🏢 House$GIS▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADAPGIS
Forward yield4123.71%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$9626865092698.99M$79.2K
Annual income after 10y$9,188,540,292,149,123,000.00$16,311.42
Total dividends collected$9597001533454.20M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$2.83$47.42

Year-by-year: ADAP vs GIS ($10,000, DRIP)

YearADAP PortfolioADAP Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$423,071$412,371.13$11,504$804.11+$411.6KADAP
2$16,757,576$16,304,890.03$13,371$1,061.65+$16.74MADAP
3$621,506,524$603,575,917.30$15,723$1,416.15+$621.49MADAP
4$21,586,020,468$20,921,008,487.80$18,735$1,911.16+$21586.00MADAP
5$702,184,533,133$679,087,491,232.05$22,660$2,613.51+$702184.51MADAP
6$21,396,610,339,981$20,645,272,889,528.59$27,874$3,627.81+$21396610.31MADAP
7$610,831,070,634,019$587,936,697,570,239.40$34,947$5,121.52+$610831070.60MADAP
8$16,339,976,526,915,468$15,686,387,281,337,064.00$44,762$7,369.21+$16339976526.87MADAP
9$409,649,346,308,286,900$392,165,571,424,487,360.00$58,728$10,832.80+$409649346308.23MADAP
10$9,626,865,092,698,990,000$9,188,540,292,149,123,000.00$79,151$16,311.42+$9626865092698.91MADAP

ADAP vs GIS: Complete Analysis 2026

ADAPStock

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full ADAP Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this ADAP vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADAP vs SCHDADAP vs JEPIADAP vs OADAP vs KOADAP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.